CVspectrum.org -- CE CENTER -- The Interplay of Dyslipidemia and Inflammation: Reducing Cardiovascular Risk in Diverse Patient Populations

	SIGN IN

	Remember Me Forgot Password?

Advanced Search >>

Expert Content:
> Editorials
> Q & A

Events:
> Upcoming

Send This Page By E-mail
Print this page

The Interplay of Dyslipidemia and Inflammation: Reducing Cardiovascular Risk in Diverse Patient Populations

Released: 2-28-05

Jointly sponsored by:

and

The FCG Institute for Continuing Education gratefully acknowledges an educational grant from AstraZeneca Pharmaceuticals LP in support of this continuing educational resource.

This Newsletter has been developed and implemented in a scientifically rigorous manner under direction from the APOLLO Steering Committee members. Due diligence was followed to ensure fair balance and medical accuracy.

Faculty Disclosure Statement
It is the policy of the FCG Institute for Continuing Education to ensure independence, balance, objectivity, and scientific rigor and integrity in all its slide resource kit activities. Faculty must disclose to the participants any significant relationships with commercial companies whose products or devices may be mentioned in faculty presentations or with the commercial supporter of this activity. Disclosure information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations. Faculty disclosure statements can be found with their biographical sketches.

Faculty Disclosure

Newsletter

Click here to access the Newsletter

MORE CONTINUING EDUCATION

You can access more online and offline continuing education activities through these areas:

Supported by educational grants from Abbott Laboratories, Daiichi-Sankyo, Inc., and Eli Lilly and Company.
Supported by an educational grant from Molecular Insight Pharmaceuticals, Inc.